We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+82.04%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$3.41B
AUM Growth
+$1.01B
Cap. Flow
-$118M
Cap. Flow %
-3.45%
Top 10 Hldgs %
73.51%
Holding
40
New
7
Increased
9
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$105M
2
QURE icon
uniQure
QURE
+$73.3M
3
IMMU
Immunomedics Inc
IMMU
+$61.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.8M
5
CUE icon
Cue Biopharma
CUE
+$19.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$126M
2
PCRX icon
Pacira BioSciences
PCRX
+$60.9M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.5M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$40.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Miscellaneous 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$518M 15.22%
24,500,000
+3,500,000
+17% +$61.7M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$496M 14.57%
3,850,200
+100,200
+3% +$9.66M
ASND icon
3
Ascendis Pharma A/S
ASND
$15.8B
$259M 7.62%
1,865,000
-105,000
-5% -$11.7M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$4.24B
$244M 7.17%
8,826,039
-1,775,000
-17% -$40.4M
SRPT icon
5
Sarepta Therapeutics
SRPT
$2.19B
$227M 6.67%
1,760,000
+82,000
+5% +$8.28M
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$172M 5.05%
+3,650,000
New +$105M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.5B
$169M 4.97%
2,000,000
-437,100
-18% -$33M
ARGX icon
8
argenx
ARGX
$61.3B
$150M 4.41%
936,500
+101,500
+12% +$13.7M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$145M 4.25%
4,000,000
– –
QURE icon
10
uniQure
QURE
$2.99B
$122M 3.58%
1,700,000
+1,335,000
+366% +$73.3M
KPTI icon
11
Karyopharm Therapeutics
KPTI
$34.9M
$113M 3.32%
393,333
-10,000
-2% -$2.17M
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$112M 3.3%
1,540,000
-12,700
-0.8% -$770K
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$109M 3.2%
11,200,000
+100,000
+0.9% +$915K
ZGNX
14
DELISTED
Zogenix, Inc.
ZGNX
$104M 3.06%
2,000,000
+125,000
+7% +$5.72M
ATNX
15
DELISTED
Athenex, Inc. Common Stock
ATNX
$80.3M 2.36%
263,072
-31,428
-11% -$8.31M
ADVM
16
DELISTED
Adverum Biotechnologies
ADVM
$60.5M 1.78%
525,000
+100,000
+24% +$8.81M
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$58.9M 1.73%
1,560,000
-640,000
-29% -$23.9M
AMRN
18
Amarin Corp
AMRN
$294M
$40.7M 1.2%
95,000
-331,000
-78% -$126M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.1B
$31.8M 0.93%
349,000
-11,000
-3% -$1.07M
XENE icon
20
Xenon Pharmaceuticals
XENE
$5.45B
$31.5M 0.92%
2,400,000
– –
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$31.1M 0.91%
+500,000
New +$23.8M
CUE icon
22
Cue Biopharma
CUE
$230M
$29.7M 0.87%
+62,333
New +$19.6M
ALLO icon
23
Allogene Therapeutics
ALLO
$594M
$29.3M 0.86%
1,128,594
– –
BDSI
24
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$19M 0.56%
3,000,000
-4,424,867
-60% -$26M
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$13.4M 0.39%
+1,550,000
New +$8.7M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Avoro Capital Advisors held 40 positions worth $3.41B, up 42% from $2.4B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors withdrew a net $118M in Q4 2019, closing 9 positions and reducing 11 holdings. Its most notable exit was Pacira BioSciences, an estimated $60.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avoro Capital Advisors opened a new position in Constellation Pharmaceuticals, Inc. worth $172M.

  • Avoro Capital Advisors's largest Q4 2019 buy was Constellation Pharmaceuticals, Inc.: 3,650,000 shares worth $172M.
  • Avoro Capital Advisors added most to uniQure in Q4 2019, an estimated $73.3M increase.
  • Avoro Capital Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $126M.
  • Avoro Capital Advisors fully exited Pacira BioSciences in Q4 2019, selling an estimated $60.9M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $3.41B portfolio in Q4 2019.
  • Avoro Capital Advisors opened 7 new positions and closed 9 in Q4 2019.
  • Avoro Capital Advisors's portfolio value rose 42% quarter-over-quarter to $3.41B.

Based on Avoro Capital Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.